Logout
If you want to log out click in LogOut
Immune checkpoint inhibitors are therapeutic agents designed to block inhibitory immune checkpoint pathways, restoring T-cell activity against cancer and chronic infections.
Maintaining immune homeostasis relies on a fine balance between co-stimulatory and inhibitory signals that regulate the magnitude and duration of immune responses. This balance is essential to prevent autoimmunity while enabling effective defense against pathogens and malignant cells.
Among these regulatory mechanisms, immune checkpoint inhibitors have emerged as transformative therapies. By targeting inhibitory pathways that restrain T-cell activity, these treatments restore antitumor immune responses and have reshaped modern cancer immunotherapy.
Figure 1 | Interactions with antigen-presenting cells that regulate T cell responses. (Wykes M.N. and Lewin S.R. et al 2017)
Immune checkpoint molecules are inhibitory receptors and ligands expressed on immune cells, particularly T lymphocytes. Their physiological role is to regulate antigen-specific immune responses and maintain immune tolerance.
Through modulation of multiple intracellular signaling pathways, immune checkpoint regulation controls:
In cancer and chronic infections, these inhibitory mechanisms are frequently hijacked, leading to immune exhaustion and impaired immune surveillance.
Immune checkpoint inhibitors are monoclonal antibodies designed to block inhibitory receptor–ligand interactions. The most extensively studied targets include:
By blocking these interactions, immune checkpoint inhibitors:
This immune reactivation underlies the durable clinical responses observed in multiple cancer types.
Immune checkpoint inhibitors have demonstrated significant clinical benefit in cancers such as:
However, only a subset of patients responds to immune checkpoint blockade. Understanding the molecular basis of response and resistance remains a major challenge in oncology.
Immune checkpoint pathways are also involved in infectious diseases:
These observations highlight the broader relevance of immune checkpoint regulation beyond oncology.
Because patient responses to immune checkpoint inhibitors vary widely, biomarker discovery is critical.
Monitoring gene expression of immune checkpoint molecules and associated immune pathways can help:
Support patient stratification strategies
Gene expression profiling provides a powerful approach to investigate immune regulation by capturing:
Crosstalk with JAK-STAT, NF-κB, and cytokine signaling pathways
For a pathway-level overview of immune checkpoint regulation and biomarkers, visit our Immune Checkpoints signaling pathway page.
Immune Checkpoints signaling pathway page.
Immune checkpoint inhibitors have revolutionized cancer immunotherapy by restoring antitumor immune responses. Continued progress depends on a deeper understanding of immune checkpoint biology and the identification of robust biomarkers.
Integrating immune checkpoint research with targeted gene expression analysis offers a powerful strategy to advance immunotherapy development and precision medicine.